Cayman Chemical

Cayman Chemical is a biotechnology company based in the United States, founded in 1980. The company's slogan "Helping Make Research Possible" reflects its commitment to providing the scientific community with the necessary tools for advancement. Offering a wide array of products such as assay kits, antibodies, proteins, and biochemicals, Cayman Chemical supports research in diverse areas including cancer, inflammation, neuroscience, diabetes, and more. One of the company's notable achievements is its leadership in the field of emerging drugs of abuse, supplying high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and academic research institutions for forensic analyses. With a team of 100 in-house scientists who also provide research support and contract research services, Cayman Chemical goes beyond product provision to facilitate scientific progress. In terms of investment, Cayman Chemical received a $1.50M grant investment on 25th April 2019 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institutes of Health. This funding signifies the recognition and support from prominent institutions within the scientific community, further validating the company's contributions to research and innovation.